Editorial: infliximab trough cut-off for perianal Crohn's disease – another piece of the therapeutic drug monitoring-guided infliximab dosing puzzle

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 9, 2017, Pages 1279-1280

  Mitrev, N ^a   Kariyawasam, V ^a   Leong, R W ^a  

^a ANZAC Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ANUS FISTULA; BIOASSAY; CROHN DISEASE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MONITORING; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC ASSOCIATION; HOMOGENEOUS MOBILITY SHIFT ASSAY; HUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PUBLICATION; REMISSION; TREATMENT RESPONSE; WOUND HEALING; RECTUM FISTULA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CROHN DISEASE; DRUG MONITORING; GASTROINTESTINAL AGENTS; HUMANS; INFLIXIMAB; RECTAL FISTULA; TREATMENT OUTCOME;

EID: 85016775588     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.14020     Document Type: Editorial

References (6)

1. Mitrev N, Leong RW. Therapeutic drug monitoring of anti-tumour necrosis factor-alpha agents in inflammatory bowel disease. Expert Opin Drug Saf 2017; 16: 303–17.
2. Yarur AJ, Kanagala V, Stein DJ, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. Aliment Pharmacol Ther. 2017; 45: 933–40.
3. Ungar B, Levy I, Yavne Y, et al. Optimizing Anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2016; 14: 550–7.
4. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398–405.
5. Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn's disease. J Crohn's Colitis 2016; pii: jjw182 [Epub ahead of print].
6. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109: 1055–64.